Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
Lipid Absorption01:24

Lipid Absorption

708
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
708
Operant Conditioning Intervention01:24

Operant Conditioning Intervention

112
Operant conditioning serves as a foundational principle in therapeutic interventions aimed at modifying maladaptive behaviors. Central to this approach is the notion that behaviors, both adaptive and maladaptive, are learned through reinforcement. By analyzing the environmental factors that reinforce problematic behaviors, clinicians can design interventions to weaken these reinforcements and replace maladaptive behaviors with healthier alternatives.
In operant conditioning, behaviors that are...
112
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

2.4K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harnessing Large-Scale Multi-Omics Data for Risk Prediction and Deep Phenotyping of Valvular Heart Diseases in the General Population.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Prenatal Acetaminophen (Paracetamol) Use and the Risk of Autism and/or Attention-Deficit/Hyperactivity Disorder Among Sibling-Matched Cohorts.

JAMA internal medicine·2026
Same author

Cardiovascular outcomes and safety associated with statin therapy for primary prevention in older adults with type 2 diabetes: A target trial emulation study.

PLoS medicine·2026
Same author

Identifying druggable proteins of the association of chronotype on breast cancer using Mendelian randomization.

Communications medicine·2026
Same author

Association of Reduction in Continuity of Care During COVID-19 Pandemic With Cardiovascular Diseases, Kidney Failure and All-Cause Mortality for People With Diabetes: A Cohort Study in Hong Kong.

Diabetes, obesity & metabolism·2026
Same author

Authors' reply: Myasthenia gravis following the initiation of statin therapy.

Journal of internal medicine·2026

Related Experiment Video

Updated: Sep 10, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Optimizing long term disease prevention with reinforcement learning: a framework for precision lipid control.

Yekai Zhou1,2,3, Ruibang Luo4,5,6, Joseph Edgar Blais7

  • 1Department of Computer Science, School of Computing and Data Science, The University of Hong Kong, Hong Kong SAR, China.

NPJ Digital Medicine
|August 27, 2025
PubMed
Summary

Duramax, a new AI framework, optimizes long-term chronic disease prevention by analyzing real-world data. It improves cardiovascular disease (CVD) risk reduction strategies, offering personalized and transparent recommendations.

More Related Videos

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.9K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

Related Experiment Videos

Last Updated: Sep 10, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.9K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

Area of Science:

  • Computational medicine
  • Artificial intelligence in healthcare
  • Preventive cardiology

Background:

  • Chronic disease prevention requires adaptive strategies beyond short-term treatment goals.
  • Current approaches may lack comprehensive insights for long-term patient survival trajectories.
  • Personalized medicine necessitates advanced analytical tools for optimizing preventive care.

Purpose of the Study:

  • Introduce Duramax, an evidence-based reinforcement learning framework.
  • Optimize long-term preventive strategies for chronic diseases, focusing on cardiovascular disease (CVD).
  • Enhance personalized disease prevention through computational analysis of health records.

Main Methods:

  • Developed Duramax, a reinforcement learning framework trained on real-world treatment data.
  • Utilized extensive datasets covering over 200 lipid-modifying drugs and 3.6 million treatment months.
  • Validated Duramax's performance on an independent cohort with over 29.7 million treatment months.

Main Results:

  • Duramax achieved a policy value of 93, significantly outperforming clinicians (value of 68).
  • Alignment with Duramax's suggestions reduced CVD risk by 6% in clinical practice.
  • Post hoc analysis confirmed Duramax's decision-making process as transparent and reasonable.

Conclusions:

  • Duramax demonstrates superior performance in optimizing long-term preventive strategies for cardiovascular disease.
  • Tailored computational analysis of health records enables highly nuanced personalized disease prevention.
  • AI-powered frameworks can significantly improve patient outcomes in chronic disease management.